Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$22.77 +1.0%	$21.37	$13.40 ▼ $25.23	$3.81B	0.64	1.97 million shs	727,842 shs
SANA Sana Biotechnology	$4.42 +2.0%	$2.67	$1.26 ▼ $7.30	$997.74M	1.86	3.90 million shs	3.00 million shs
SRRK Scholar Rock	$42.42 +3.1%	$33.32	$6.76 ▼ $46.98	$4.04B	0.33	1.31 million shs	822,261 shs
VKTX Viking Therapeutics	$32.28 +2.1%	$27.81	$18.92 ▼ $81.73	$3.63B	0.62	4.06 million shs	2.26 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+2.45%	+4.54%	+1.85%	+53.09%	+21.11%
SANA Sana Biotechnology	+3.59%	+6.91%	+71.83%	+162.42%	-36.88%
SRRK Scholar Rock	+6.17%	+11.25%	+28.07%	+34.01%	+342.00%
VKTX Viking Therapeutics	+3.03%	+4.05%	+17.32%	+32.12%	-44.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.093 of 5 stars	3.4	3.0	0.0	2.5	4.2	2.5
SANA Sana Biotechnology	3.2615 of 5 stars	3.5	3.0	0.0	2.7	3.3	0.6
SRRK Scholar Rock	3.0886 of 5 stars	1.6	1.0	4.4	2.5	3.3	0.6
VKTX Viking Therapeutics	4.6257 of 5 stars	3.5	5.0	4.7	3.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	22.42% Upside
SANA Sana Biotechnology	3.00	Buy	$9.17	107.63% Upside
SRRK Scholar Rock	3.13	Buy	$42.67	0.58% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	169.99% Upside

Current Analyst Ratings Breakdown

Latest SANA, SRRK, ACAD, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	SRRK Scholar Rock	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
7/3/2025	SANA Sana Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/25/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/18/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.98	$0.73 per share	31.23	$4.40 per share	5.18
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.12 per share	N/A
SRRK Scholar Rock	$33.19M	121.36	N/A	N/A	$3.94 per share	10.77
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	16.60	29.96	4.74	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$0.88	N/A	N/A	N/A	N/A	-86.58%	-44.49%	8/6/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.53	N/A	N/A	N/A	N/A	-118.22%	-82.01%	8/6/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)

Latest SANA, SRRK, ACAD, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	SRRK Scholar Rock	-$0.68	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	N/A	N/A	N/A	$263.07 million	N/A
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
SANA Sana Biotechnology	N/A	3.40	3.40
SRRK Scholar Rock	0.16	10.25	10.25
VKTX Viking Therapeutics	N/A	44.25	44.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
SANA Sana Biotechnology	88.23%
SRRK Scholar Rock	91.08%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
SANA Sana Biotechnology	30.10%
SRRK Scholar Rock	13.30%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
SANA Sana Biotechnology	380	225.48 million	157.61 million	Optionable
SRRK Scholar Rock	140	94.95 million	82.32 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable

SANA, SRRK, ACAD, and VKTX Headlines

Recent News About These Companies

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

July 16 at 4:19 PM | prnewswire.com

H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT

July 16 at 10:43 AM | insidermonkey.com

Kintayl Capital LP Grows Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 16 at 8:59 AM | marketbeat.com

Viking Therapeutics (VKTX) Projected to Post Quarterly Earnings on Wednesday

July 16 at 3:49 AM | marketbeat.com

The Best Stocks to Invest $1,000 In Right Now

July 15 at 4:40 AM | fool.com

Concurrent Investment Advisors LLC Buys New Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 13, 2025 | marketbeat.com

Principal Financial Group Inc. Sells 30,629 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 13, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Caas Capital Management LP

July 11, 2025 | marketbeat.com

Banque Pictet & Cie SA Takes Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 11, 2025 | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

July 10, 2025 | zacks.com

U.S. Capital Wealth Advisors LLC Sells 8,423 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 10, 2025 | marketbeat.com

Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results

July 9, 2025 | insidermonkey.com

Financial Counselors Inc. Acquires 16,823 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 9, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Trading Up 8.1% - Still a Buy?

July 8, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Cambridge Investment Research Advisors Inc.

July 8, 2025 | marketbeat.com

Better Growth Buy: Eli Lilly vs. Viking Therapeutics

July 7, 2025 | fool.com

August 22nd Options Now Available For Viking Therapeutics (VKTX)

July 5, 2025 | nasdaq.com

Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of Stock

July 4, 2025 | insidertrades.com

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

July 4, 2025 | fool.com

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

July 3, 2025 | zacks.com

Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of Stock

July 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

SANA, SRRK, ACAD, and VKTX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.77 +0.22 (+0.98%)

As of 02:39 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Sana Biotechnology NASDAQ:SANA

$4.42 +0.09 (+1.96%)

As of 02:39 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Scholar Rock NASDAQ:SRRK

$42.42 +1.27 (+3.09%)

As of 02:39 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$32.28 +0.65 (+2.06%)

As of 02:39 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time